Blog
RSS FeedPosted by Michael Wonder on 05 Jun 2021
Put Canadians first by suspending the implementation of harmful drug pricing regulations
4 June 2021 - Innovative Medicines Canada calls on the federal government to suspend the implementation of the Patented Medicines ...
Posted by Michael Wonder on 18 May 2021
Northern Ireland faces ‘huge’ rise in generic medicine prices
18 May 2021 - Large increase likely after end of Brexit grace period, warns UUP head Simon Aiken. ...
Posted by Michael Wonder on 25 Apr 2021
The price of a Vertex cystic fibrosis treatment stirs anger in Australia
23 April 2021 - The latest dustup over the cost of cystic fibrosis medicines sold by Vertex Pharmaceuticals is taking ...
Posted by Michael Wonder on 22 Apr 2021
The thorny issue of value alignment: how development-focused health technology assessment can help find win–win situations for patients and health care systems and commercial investors
20 April 2021 - We agree that there is always likely to be some tension between commercial interests and maximising societal ...
Posted by Michael Wonder on 22 Apr 2021
Bluebird’s withdrawal of therapy from Germany could chill talks over gene therapy prices across Europe
22 April 2021 - When Bluebird Bio secured European approval for its gene therapy to treat beta thalassaemia in 2019, ...
Posted by Michael Wonder on 22 Apr 2021
Novartis to discontinue sales of Piqray in Germany
21 April 2021 - The sale of Piqray (alpelisib) will be discontinued by Novartis in accordance with Section 4 (7) ...
Posted by Michael Wonder on 13 Apr 2021
Europe tries to lower drug prices with small doses of transparency
13 April 2021 - For countries in Europe, negotiating a deal with a pharma company over drug prices is the ...
Posted by Michael Wonder on 24 Jan 2021
Canada’s drug makers rattle their sabers over a government plan to control medicine spending
21 January 2021 - A majority of pharmaceutical executives in Canada say new regulations designed to cut prescription drug spending ...
Posted by Michael Wonder on 21 Jan 2021
Industry pooling helps maintain affordability of high cost drugs despite significant inflationary pressures
21 January 2021 - In 2019, the Canadian Drug Insurance Pooling Corporation's (CDIPC) high-cost drug sharing framework provided coverage to ...
Posted by Michael Wonder on 20 Jan 2021
2021 April price disclosure cycle – indicative prices
20 January 2021 - Indicative 1 April 2021 prices resulting from the 2021 April Cycle of Price Disclosure have now been ...
Posted by Michael Wonder on 09 Jan 2021
Health Canada postpones overhaul of drug pricing for 6 months
8 January 2021 - Changes meant to bring down price of prescription drugs pushed to 1 July 2021. ...
Posted by Michael Wonder on 21 Dec 2020
Price disclosure 2021 April cycle outcomes summary
21 December 2020 - The summary of price disclosure price reductions for the 2021 April Cycle has now been published. ...
Posted by Michael Wonder on 15 Nov 2020
Drug makers offer Canada 1 billion dollars to scrap some pending pricing rules
16 November 2020 - The pharmaceutical industry has made a last-ditch C$1 billion ($761 million) proposal to the Canadian government ...
Posted by Michael Wonder on 09 Nov 2020
Vary drug prices for different conditions, say health experts
9 November 2020 - The NHS could improve patients’ access to new cancer treatments by paying different prices for drugs ...
Posted by Michael Wonder on 02 Nov 2020
PBAC recommends price increase for paracetamol
30 October 2020 - A fascinating insight from the first round of Public Summary Documents from the July 2020 PBAC ...